Reference no: EM133990871

Question

1. Contrast the rationales given by NIH Director Francis Collins versus Attorney Christopher Robertson on requiring informed consent for using de-identified (anonymized) human samples for research and development? How would you refute each of these opposing perspectives?

2. Who do you think should "own" samples derived from a human donor? What factors do you think should be considered?

3. Propose a tiered consent system for research applications of human biopsy tissue. For example, consider who would provide consent & what kind of consent would be required in the following situations:

living donors vs deceased donors

anonymized vs non-anonymized donors

commercialized human cell lines versus use cells used for only a single research project (non-commercialized)

4. Who profits from commercialization AND how do the costs of commercialization figure into the issue of ownership and compensation?

5. What are the steps in commercialization & who carries out all those steps ?

6. When and how are family members of the donor sample affected? Discuss the issue of compensation for:

the donor

the donor's family

the costs of commercialization

7. List 3 key discoveries and medical advancements developed with HeLa cells.